Compare AbbVie Inc (ABBV) vs Firy Inc. (FIRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Firy Inc. — how do they compare? AbbVie Inc trades at $248.8 (market cap $441.94B), while Firy Inc. trades at $9.98 (market cap $159.51M). The key difference: AbbVie Inc is far larger — about 2770.6× Firy Inc.'s market cap, and AbbVie Inc pays a 2.77% dividend while Firy Inc. pays none. Which is the better fit depends on your goals.
| ABBV | FIRY | |
|---|---|---|
Market Cap | $441.94B | $159.51M |
Sector | Health | Consumer Cyclical |
52-Week High | $263.58 | $12.45 |
52-Week Low | $197.38 | $2.28 |
Enterprise Value | $506.19B | $103.18M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.94, up 0.82% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with $61.16B revenue in 2025 and consistent earnings beats, though net margins have compressed from 20.4% in 2022 to 6.9%. Recent positive Phase 2 data for ELAHERE in ovarian cancer and institutional accumulation signal confidence. Technical indicators show support at $248 and resistance at $251, with the stock trading near analyst consensus targets.
Outlook remains positive with 70.7% analyst buy ratings and $278.69 price target, representing 11.5% upside. Key opportunities include immunology growth from Skyrizi/Rinvoq and pipeline advancements. Risks include patent cliffs in the 2030s, debt levels at 50.4% of assets, and margin pressure from competitive and pricing headwinds. The dividend yield and earnings recovery in 2026 forecast support the bullish case.
FIRY (formerly Skillz Inc.) trades at $9.98, down 4.77% today, with a bullish technical signal from moving averages. The company shows persistent losses with a -67.38% net margin in 2025 despite an 87.75% gross margin, while revenue declined from $270M in 2022 to $104M in 2025. Recent developments include a legal victory securing $719M and a corporate rebranding to FIRY.
The outlook remains challenging due to sustained negative cash flows and profitability issues, though the legal win provides a potential catalyst. Analyst sentiment is mixed with 60% hold ratings. Key risks include execution on profitability and competitive pressures in mobile gaming.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
